

Hypertension in pregnancy

Dr Mandana Master
Obstetrician and Gynaecologist
Burnside Women's Health
Women's and Children's Hospital



Definition

- Normal pregnancy is characterised by a drop in BP- rising towards pre conception levels by term
- HT in pregnancy defined as
 - Systolic ≥ 140 mmHg and /or
 - Diastolic ≥ 90 mmHg
 - Rise in BP from booking $> 30/15$ mmHg
- Severe HT $\geq 160/110$ mmHg- needs urgent treatment
 - Risk of cerebral haemorrhage, PRES



Measurement

- Measurements should be confirmed by repeated readings over several hours
- Sitting position
- appropriate cuff size
- Both arms at initial visit



Classification of hypertensive disorders

- Preeclampsia
- Gestational HT
- Chronic HT
 - Essential
 - Secondary
 - CKD, renal artery stenosis, DM, SLE, phaeochromocytoma, Cushing's, coarctation
 - White coat (needs 24hr ambulatory monitoring to avoid inappropriate intervention)
- Preeclampsia superimposed on chronic HT

Gestational HT

- New onset HT after 20/40 with no features of preeclampsia
- Return of BP to normal within 3/12 post-partum
- Investigations- 25% will develop PE
 - Urine PCR
 - FBC
 - EUC, LFT
 - US assessment of fetal growth, AFI, dopplers
- Assess for proteinuria 1-2x week
- PE bloods weekly



Predictive Value of the sFlt-1:PlGF Ratio

- The ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) is elevated in pregnant women before the clinical onset of preeclampsia
 - <38 continue routine outpatient care
 - 38-110-> discharge and re assess in 1-2 weeks
 - >100-200-> admission
 - >200 delivery likely within 48 hours
-
- PROGNOSIS (Prediction of Short-Term Outcome in Pregnant Women with Suspected Preeclampsia Study) NEJM 2016

Surveillance in Chronic HT

- Assess for proteinuria each visit
- PE bloods if sudden increase in BP or new proteinuria
- Poor control of HT in first trimester is associated with increased fetal and maternal morbidity and mortality- up to 3x PNMR
- Target BP to $<140/90$ to reduce adverse pregnancy outcomes with no increase in SGA
 - Chronic Hypertension and Pregnancy (CHAP) trial, NEJM 2022



Treatment

- Methyldopa
 - 250-750mg TDS
 - Side effects: dry mouth, sedation, depression
 - Contraindication: depression
- Labetolol
 - 100-400mg TDS
 - Side effects: bradycardia, bronchospasm, nausea, scalp tingling (resolves)
 - Contraindications: asthma
- Nifedipine
 - 20-60mg SR BD
 - Side effects: headache, flushing, tachycardia, constipation
 - Contraindications: aortic stenosis

Treatment

- ACE I and ARB are contraindicated in pregnancy
- Use in 3rd trimester has been associated with fetal death and neonatal renal failure
- Breast feeding
 - Methyldopa
 - Labetolol
 - Nifedipine
 - Enalapril, captopril, quinapril
- Commonly swap to enalapril for easier dosing regime



Pre-eclampsia

HT arises after 20 weeks gestation + one or more other organ system

- Renal
 - Urine PCR $\geq 30\text{mg}/\text{mmol}$
 - Cr > 90
 - Oliguria $< 20\text{mL}/\text{hr}$
- Haematological
 - Plt $< 100\ 000$
 - Haemolysis on blood film, raised bilirubin or LDH, decreased haptoglobin
- Liver
 - Raised transaminases
 - Severe epigastric or RUQ pain
- Neurological
 - Hyperreflexia with sustained clonus
 - Persistent headache, visual disturbance
- Pulmonary oedema
- IUGR
 - Abnormal UAD or oligohydramnios



HELLP syndrome

- Subset of women with severe PE
- **H**aemolysis, **E**levated **L**iver enzymes, **L**ow **P**latelets
- Expectant management is harmful with a 6.3% incidence of maternal death and an increased risk of placental abruption



Risk Factors for Preeclampsia

• Previous PE	RR 7
• Chronic HT	RR 7
• APLS	RR 9.7
• Type 1 or 2 DM	RR 3.5
• Multiple pregnancy	RR 2.9
• Nulliparity	RR 2.9
• FamHx PE	RR 2.9
• Maternal age \geq 40	RR 1.9



Risk factors for Preeclampsia

- BMI 25-30 RR 1.7
- BMI > 30 RR 2.7
- BMI > 40 RR 4



BMI > 30

- Preconception folic acid 5mg
- 5-9kg weight gain for whole pregnancy
- Regular moderate exercise 30-60 mins daily
- Early OGTT (16/40)
- Low dose aspirin
- Consider thromboprophylaxis



Protective factors

- Smoking
- High fruit intake
- > 12 months to conceive



Pre-eclampsia screening

- PAPP-A < 0.4
- Ask for uterine artery dopplers at NT scan and morphology
 - Raised PI >95th centile or notching
- Commence aspirin
- Growth surveillance



Preventing preeclampsia

- Low dose aspirin
 - Pathophysiology of PE is an imbalance between prostaglandins, prostacyclin and thromboxane-> aspirin corrects this imbalance by inhibiting platelet aggregation and dilating blood vessels
 - Optimal dose is 150mg commenced before 16/40
 - Cease around 36/40
- Calcium 1.5g/day
 - Low Ca may increase BP by stimulating PTH or renin release ->increasing intracellular Ca in vascular smooth muscle -> vasoconstriction
 - Ca reduces smooth muscle contractility and affects uteroplacental blood flow by lowering resistance in uterine and umbilical arteries
 - Offer to those with low dietary Ca intake

Maternal Indications for delivery

- Gestation $\geq 37/40$
- Uncontrollable HT
- Deteriorating platelets, LFT, renal function
- Abruptio
- Focal neurological symptoms or eclampsia
- APO



Fetal Indications for delivery

- Severe IUGR
- Non-reassuring fetal status
- abruption



Postnatal thromboprophylaxis

- Pre-eclampsia AND
 - CS
 - Preterm delivery
 - Multiple pregnancy
 - Stillbirth
 - Instrumental delivery
 - Labour >24 hours
 - PPH >1L
- For 10 days postpartum



Postpartum

- Bloods often worsen for the first 3 days before improving
- Avoid NSAIDs
- Most HT has settled by 2 weeks but may persist for 3/12
- Risk of recurrence in subsequent pregnancy



Long term consequences of pre-eclampsia

- Increased risk of CVD
 - HT
 - IHD
 - Stroke
 - VTE
- Children born to a pregnancy complicated by PE also have increased CV risk



Follow up

- Annual BP
- Lipids and blood glucose assessment at least every 5 years



Summary

- BP 140/90 in pregnancy is not normal
- Surveillance for both mother and baby- increased maternal and fetal morbidity
- BP 160/110 requires urgent evaluation and treatment
- Aim for BP <140/90
- Delivery by 37/40 if PE develops
- Thromboprophylaxis
- Long term follow up for CVD
- Reducing risk of recurrence- aspirin, Ca



Fetal Growth

- SGA
 - EFW < 10%
 - Symmetrically small baby
- LGA
 - EFW > 90%
- IUGR
 - EFW < 10%
 - Head sparing -> HC/AC discordance
 - Abnormal dopplers
 - Oligohydramnios
 - Serial US evidence of growth arrest



Causes

- Incorrect dating
- Constitutionally small (customised growth charts)
- Genetic/chromosomal defects
- Infection (TORCH screen)
- Uteroplacental insufficiency



Risk factors for IUGR

- Maternal age >40
- Smoking, cocaine, amphetamines, ETOH
- Socioeconomic and nutritional factors
- Daily vigorous exercise
- Chronic HT, DM, renal impairment, APLS
- Previous SGA, stillbirth, maternal or paternal SGA
- If high risk for IUGR start aspirin before 16/40



Pregnancy developments that increase risk

- Antepartum haemorrhage
- Echogenic bowel
- Pre-eclampsia
- Low maternal weight gain
- PAPP-A <0.4MOM or HCG <0.5MOM

- Serial growth US



Sequae of IUGR

- Stillbirth
- Neurodevelopmental delays
- Increased risks of vascular disease and diabetes in adulthood



Assessment

- SFH
 - Patient should be supine with legs extended, bladder empty
 - Measure from fundus to pubic symphysis along uterine axis
 - If SFH inaccurate due to BMI, fibroids -> arrange serial growth US



If risk factors for IUGR

- Uterine artery doppler at NT or morphology US
- If Uterine artery doppler PI > 95% or notched -> serial growth US
- If Uterine artery doppler normal then growth US 28, 32 and 36 weeks



Ultrasound

- Dating US 8-12 weeks
 - If >5 days discrepancy use EDC from US
- Growth scans no closer than 2 weeks apart
 - Review serial EFW and AC- assesses liver size and hence glycogen stores
 - Oligohydramnios
- AFI and dopplers can be done more frequently
 - UAD -> uteroplacental blood flow
 - Middle Cerebral Artery -> fetal anaemia (PSV), head sparing (PI)
 - Ductus Venosus



Timing of delivery

- <30/40 with absent or reversed end diastolic flow- delivery indicated when DV becomes abnormal
- After 24/40 or >500g
- 30-32/40 with reversed or absent EDF
- 34/40 with abnormal (increased resistance) UAD
- SGA with normal dopplers aim for 37-38/40
- Mode of delivery
 - Often small babies with abnormal dopplers will not tolerate labour
 - CS if AEDF or REDF
 - SEND THE PLACENTA

Summary

- Assess for risk factors
- Ask for uterine artery dopplers at morphology (and cervical length)
- Serial growth scans every 2-3 weeks
- Assess for parameters crossing growth curve centiles, AC or EFW <10%, abnormal dopplers, oligohydramnios

